Sesen Bio Reports Q3 EPS and Revenue

Trending News ☀️

Sesen Bio ($NASDAQ:SESN), Inc. is a biopharmaceutical company focused on the development and commercialization of targeted fusion protein therapies to treat patients with cancer. The company’s lead product candidate, Vicinium, is a targeted fusion protein that is in Phase 3 clinical trials for the treatment of high-grade non-muscle invasive bladder cancer. Sesen Bio reported GAAP EPS of $0.10 for the third quarter of 2022 and revenue of $40 million.

Looking ahead, Sesen Bio is focused on completing the Phase 3 clinical trials for Vicinium and preparing for commercialization. The company is also working on advancing its pipeline of product candidates and expanding its indications for Vicinium.

Earnings

The decrease was primarily due to lower net product sales of Vicinium in the United States and higher research and development expenses. Sesen Bio also announced that it has initiated a Phase 3 clinical trial of Vicinium in patients with high-grade non-muscle invasive bladder cancer who are ineligible for or have failed prior Bacillus Calmette-Guérin therapy. The company expects to report top-line data from this trial in the second half of 2021.

About the Company

Market Price

Sesen Bio‘s stock opened at $0.6 on Monday and closed at $0.5, up by 0.6% from last closing price of $0.5. Live Quote…

VI Analysis

Sesen Bio is a clinical-stage biopharmaceutical company focused on developing targeted fusion protein therapeutics for the treatment of cancer. The company’s lead product candidate, Vicinium, is a targeted fusion protein that is currently in Phase 3 clinical trials for the treatment of non-muscle invasive bladder cancer. According to VI’s Risk Rating, Sesen Bio is a high risk investment in terms of financial and business aspects. The company has 4 risk warnings in income sheet, balance sheet, cashflow statement, financial journal. More…

VI Peers

The healthcare sector is competitive, and companies are always vying for market share. Sesen Bio Inc is no different, and it competes against Gossamer Bio Inc, Galmed Pharmaceuticals Ltd, and ARCA biopharma Inc. in the development and commercialization of treatments for cancer and other diseases. While each company has its own strengths and weaknesses, Sesen Bio Inc has proven to be a formidable competitor.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of immunology, inflammation and oncology. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.

As of 2022, Gossamer Bio has a market cap of 1.17B and a ROE of -3124.66%. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.

– Galmed Pharmaceuticals Ltd ($NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic solutions targeting liver diseases. The company’s lead product candidate, Aramchol, is a once-daily, oral treatment for non-alcoholic steatohepatitis (NASH). Galmed is planning to initiate a Phase III clinical trial for Aramchol in 2020. The company has a market cap of 9.04M as of 2022 and a Return on Equity of -111.62%.

– ARCA biopharma Inc ($NASDAQ:ABIO)

ACRA biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of cancer and other diseases. The company has a market cap of 29.54M as of 2022 and a Return on Equity of -22.71%. ACRA biopharma Inc was founded in 2006 and is headquartered in San Diego, CA.

Summary

Investors may want to consider buying shares of Sesen Bio, a clinical-stage biopharmaceutical company focused on developing targeted fusion protein therapies to treat cancer. The company’s lead product candidate is Vicinium, which is in Phase 3 clinical trials for the treatment of high-grade non-muscle invasive bladder cancer. Sesen Bio also has several other product candidates in various stages of development.

Sesen Bio’s products have the potential to be best-in-class or first-in-class therapies, and the company’s pipeline includes several other promising product candidates. Given the potential of its products and pipeline, Sesen Bio is a company that investors may want to keep an eye on.